It's How Medicine Should Be®

Translate

French German Italian Portuguese Russian

Study Using VLX 1570 for Treatment of Relapsed or Relapsed and Refractory Multiple Myeloma

Clinical Trial Title: 
Clinical trial with study drug and low-dose dexamethasone in relapsed or relapsed and refractory multiple myeloma.
Clinical Trial Protocol ID: 
16070804
Clinical Trial Investigator Name: 
Agne Paner, MD
Clinical Trial Protocol Description: 

To provide study drug and low-dose dexamethasone in treatment for patients with relapsed or relapsed and refractory multiple myeloma and to collect additional data on treatment safety.

Clinical Trial Eligibility Criteria: 

In order to participate you must meet the following criteria:

  • Have a diagnosis of relapsed or relapsed and refractory multiple myeloma, or intolerant to established therapy following at least 2 prior therapies. Prior therapies must include at least one immunomodulatory drug and one proteasome inhibitor.
  • Have measureable disease.
  • Have GFR > 30 mL/min.
  • Have ANC > 1000, Hgb > 8 (transfusion permitted provided the anemia is judged to be disease related) and PLT > 75,000.

You will be excluded from the study if any of the following criteria apply to you:

  • Have hypertension or diabetes not adequately controlled with current medication.
  • Have known active hepatitis B or C infection or HIV infection.
  • Have significant cardiovascular disease.
  • Have a known intolerance to steroids or H1/H2 antagonists.
  • Have been diagnosed with plasma cell leukemia, POEMS syndrome or amyloidosis.

This is a partial list of inclusion and exclusion criteria.

Clinical Trial Area: 
Blood Disorders and Hematologic Cancers
Contact Phone: 
(312) 942-4685
Contact Name: 
Christine Deskovich RN, BSN, OCN